Document:

EXHIBIT 10.7

GARY BROWNELL

PROMISSORY NOTE
Aug 1, 2000

$45,454.00

     FOR VALUE RECEIVED, the undersigned, each as principal, jointly and
severally, promise(s) to pay to the order of INNOVATIVE MEDICAL SERVICES at El
Cajon, CA the sum of $45,454.00 DOLLARS with interest thereon from Aug 1, 2000,
at the rate of 6.0 percent per annum due and payable at July 31, 2001.
     The parties do not intend this note to obligate the signers of this note to
pay any money in excess of the legal rate of interest allowed by the laws of the
state of CA. If the signers do pay any money in excess of the legal rate of
interest allowed by the laws of the state of CA, the holder shall apply such
excess money to reduce the principal amount the signers owe the holder.
     Interest shall first be deducted from the payment, and any balance shall be
applied on principal.
     Principal and interest not paid when due shall draw interest at the rate of
10%percent per annum. Upon default in payment of any interest, or any
installment of principal, the whole amount then unpaid shall become immediately
due and payable at the option of the holder without notice. The undersigned, in
case of suit on this note, agrees to pay attorney's fees.
     Makers, endorsers and sureties waive demand of payment, notice of
nonpayment, protest and notice. Sureties, endorsers and guarantors agree to all
of the provisions of this note, and consent that the time or times of payment of
all or any part hereof may be extended after maturity, from time to time,
without notice.

/s/ Gary Brownell            August 1, 2000
-----------------            -------------------------------
Signature                    DateEXHIBIT 10.4

                                   ASSIGNMENT

In consideration of One Dollar and other good and valuable consideration,
receipt of which is hereby acknowledged, Gerald Weaver, PhD. of hereby sell,
transfer, sets over and assign unto Innovative Medical Services as ASSIGNEE, a
corporation existing under the laws of the California, having a mailing address
of 1725 Gillespie Way, El Cajon, CA 92020, and the successors, assigns,
nominees, or other legal representatives of said ASSIGNEE, the entire right,
title and interest in and to the Improvements in the boric acid/glycerin product
and better described as a:

Formulation consisting of colloidal granules of boric acid encapsulated in a
humidity resistant coating. The coating consists of ingredients that are both
appetizing and aromatically appealing as a target for insects. For ease of
application, the bait presently manifests itself in the form of non-aqueous
paste. Insects consume the bait and return to the aggregate. In time, their
digestive acids penetrate the protective coasting and the lethal boric acid is
release. Additional deaths are perpetuated at the aggregate site by both the
protected boric acid adhering to the body and legs of the exposed insect as
well as from cannibalism of affected bodies contaminated with undigested boric
acid granules. The time-delayed effect of this formulation insures that the
insect dies at the nest-site rather than at the bait-site so that the source of
their social disorientation is not exposed. The aggregate is often eliminated
within 3-4 days through this process yet the bait will remain active for months
to come

Invented by me and the application for United States patent therefore, executed
concurrently herewith and all original and reissued patents granted therefore,
and all divisions and continuations, thereof, including the subject-matter of
any and all claims which may be obtained in every such patent, and all of my
entire right, title and interest in and to apply for and obtain patents in
countries foreign to the United States, and in and to any Letters Patent which
may be granted thereon in such foreign countries, and authorized and request the
Commissioner of Patents of the United States, and any official of any country or
countries foreign to the United States whose duty it is to issue patents on
applications as aforesaid, to issue said Letters Patent to said ASSIGNEE, the
successors, assigns, nominees or other legal representatives of said ASSIGNEE,
as assignee and owner of the entire interest of said ASSIGNEE, and covenant that
I have full right to convey my entire interest herein assigned and that I will
communicate to said ASSIGNEE, the successors, assigns, nominees or other legal
representatives of said ASSIGNEE, all facts known to me respecting said
invention, whenever requested, and testify in any legal proceedings, sign all
lawful papers, execute and deliver all divisional, continuing and reissue
applications, make all rightful oaths and do all lawful acts requisite for the
application of such divisional, continuing or reissue applications, or the
procuring thereof, and that if and when said ASSIGNEE, the successors, assigns,
nominees or other legal representatives of said ASSIGNEE desire to file a
disclaimer relating thereto I will, upon request, sign and deliver all lawful
papers requisite for the filing of such disclaimer, and I further covenant and
agree that I will, at any time upon request, do everything legally possible to
aid said ASSIGNEE, the successors, assigns, nominees or other legal
representatives of said ASSIGNEE, either in the name of said ASSIGNEE or my own
name, to apply for, obtain and enforce proper patent protection for said
Improvements in all countries, including priority rights granted to patents in
foreign countries according to the International Convention of 1883 and all the
laws and treaties in force,

<PAGE>

all without further consideration but at the expense of said ASSIGNEE, the
successors, assigns, nominees or other legal representatives of said ASSIGNEE.

1/4/01                                  /s/ Gerald Weaver
------                                  -----------------
Date                                    Gerald Weaver PhD.

<PAGE>

                            MEMORANDUM OF AGREEMENT

                                    12/22/00

This memorandum of agreement is entered into as of the 22nd day of December,
2000 at El Cajon California between Innovative Medical Services (hereinafter
"IMS") and JERRY WEAVER (hereinafter"WEAVER").

WHEREAS IMS is desirous of obtaining the boric acid (i.e. RoachX) technology and
of employing WEAVER to head its pesticide division, and WEAVER is desirous of
being so employed, the parties and entering into this memorandum of agreement
prior to reducing the terms and conditions of their agreement to an employment
and confidentiality agreement to be prepared and executed hereafter.

WEAVER represents and warrants that he is the sole owner and inventor of this
boric acid technology and is the owner of the pending U.S. patent to RoachX, as
well as the holder of its approvals by the U.S. Environmental Protection Agency
and U.S. Department of Agriculture, as well as many state EPAs, and that no
other person, firm or entity has the right or ability to prevent their use by
IMS once Weaver is employed by it.

WEAVER has elected to accept the compensation package described in Exhibit "A"
as described therein.

This memorandum and the obligations of IMS contained herein are subject to final
approval by the IMS board of directors at its Board Meeting to take place
January 8th, 2001.

/s/ Michael L. Krall                         /s/ Gerald Weaver, PhD
---------------------------                  ----------------------
Innovative Medical Services                  Gerald Weaver PhD

<PAGE>

Initialed:  GW
            MLK
                                  EXHIBIT "A"

GERALD WEAVER PhD hereby elects to receive his compensation from IMS pursuant to
the to be executed employment agreement with it as follows:

     1)   Base salary of $100,000 per annum plus employee benefits currently
          afforded all IMS employees as of the date of execution hereof.

     2)   An option to purchase (or cashless exercise) 200,000 shares of the
          common stock of IMS at the market price prevailing on the date of
          exercise thereof.

     3)   $50,000 due and payable within 30 days of the execution of this
          Memorandum of Agreement.

     4)   $450,000 payable at $50,000 due when each $1 million in net sales of
          RoachX has occurred.

                                  EXHIBIT "B"

     1)   Base salary of $100,000 per annum plus employee benefits currently
          afforded all IMS employees as of the date of execution hereof.

     2)   An option to purchase (or cashless exercise) 200,000 shares of the
          common stock of IMS at the market price prevailing on the date of
          exercise thereof.

     3)   $50,000 due and payable within 30 days of the execution of this
          Memorandum of Agreement.

     4)   $250,000 payable at $25,000 due when each $1 million in net sales of
          RoachX has occurred, and 250,000 option to purchase the common stock
          of IMS at the market price prevailing on the date of execution hereof,
          and vesting at the rate of 25,000 shares when each $1 million in net
          sales of RoachX has occurred.Exhibit 10.5

[THIS EXHIBIT HAS BLACKED OUT CERTIN FINANCIAL INFORMATION IN SECTIONS 4.2 AND
5.3 WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED]

                               IMS-dodo Agreement

THIS IMS-dodo Agreement (hereinafter "Agreement") is made and entered into as of
March 5, 2001 (the "Effective Date") by and between:

(i)      IMS, Innovative Medical Services, a business duly organized under the
         laws of the State of California with its principal of place of business
         at 1725 Gillespie Way, El Cajon, CA 92020 (hereinafter "IMS"); and,

(ii)     dodo & Company, a business duly organized and doing business under the
         Laws of Korea with its principal place of business at Dabo Bldg., 577
         Shinsa-Dong, Kangnam-Ku, Seoul, Korea (hereinafter "dodo"). Each shall
         be designated "Party" and collectively, the "Parties" hereinafter with
         reference to the following:

                                    RECITALS

The following provisions form the basis for, and are hereby made a part of, this
Agreement:

A.   WHEREAS IMS (Innovative Medical Services) is a US corporation in the
     business of manufacturing and developing array of products and is being
     traded on the Nasdaq Small Cap, located in El Cajon, California;

B.   WHEREAS dodo is a Korean company doing business in the arena of cosmetics
     and beauty enhancement products; and

C.   WHEREAS THE PARTIES, now mutually desire to establish and maintain a
     relationship pursuant to which IMS, as the holder of proprietary rights to
     Axen, grant dodo an exclusive right to utilize Axen to formulate dodo's
     premium brand cosmetic line for the purposes of manufacturing and
     distribution of dodo Axen-based products to Korean market and non-exclusive
     rights to distribute Products to dodo's normal marketing channels in
     countries other than Korea.

                                    AGREEMENT

NOW THEREFORE, in consideration of the mutual promises and mutual covenants
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree to all of
the following provisions:

                             ARTICLE 1 - DEFINITIONS

1.1  Axen: shall mean the non-toxic, environmentally friendly silver ion (Ag+)
     based aqueous disinfectant formulated for the specific use as prevention
     against contamination by potentially pathogenic bacteria and viruses. Axen
     has been approved by the U.S. Patent Office and is pending issuance. Axen
     is protected under U.S. Patent Application Number 09/169.229, allowed on
     July 18, 2000.

1.2  Product: shall mean all products and technologies of IMS utilizing Axen and
     its derivative technologies as used in cosmetic products.
<PAGE>
1.3  dodo Products: shall mean all cosmetic related products developed by dodo
     with the aid of IMS, utilizing Axen as its active ingredient and shall
     include among others all Silverion line of products.

1.4  Agreement: shall mean this contract being entered in to by and between IMS
     and dodo.

1.5  Effective Date: shall mean March 5, 2001. However, a formal signing
     ceremony for official publicizing of this Agreement is to be held on March
     16, 2001 at Seoul, Korea where the Parties shall be signing a document not
     inconsistent with the terms and provisions of this Agreement, solely for
     the purposes of memorializing this Agreement.

1.6  Know-how: means all technology, techniques, processes, methods and other
     trade secrets and confidential information developed or controlled by IMS
     and disclosed to dodo during the Term of this Agreement, and relating to
     the manufacturing and or/ packaging of a Product, whether or not any such
     Know-how is covered or protected by any Patents.

1.7  Patents: means and includes any United States or corresponding foreign
     Patents relating to Axen method of formulation and conformed chemistry of
     Axen and any continuations, continuations-in-part, divisions and/or
     reissues thereof that relate to Axen.

1.8  Quarter: means a calendar quarter during the Term hereof, except that the
     first Quarter shall be from the Effective Date hereof to the end of the
     then current calendar quarter.

1.9  Term: means the Term of this Agreement, as set forth and defined in article
     5 of this Agreement.

1.10 Territory: means the Territory as set forth and defined in article 3 of
     this Agreement.

1.11 IMSA: means Innovative Medical Services Asia, a business under
     incorporation process under the appropriate laws of the Republic of Korea,
     and will have its principal place of business at Hanra Classic Officetel,
     Suite 710, Yeoksam-Dong, Kangnam-Ku, 824-11, Seoul, Korea.

                        ARTICLE 2 - TECHNOLOGY OWNERSHIP

2.1  Parties acknowledge the ownership and Intellectual Property Rights of IMS,
     according to the following:

    2.1.1 The term "Intellectual Property Rights" shall mean all forms of
          proprietary rights, titles, interests, and ownership relating to
          patents, copyrights, trademarks, trade dresses, trade secrets,
          know-how, mask works, droit moral (moral rights), and all similar
          rights of every type that may exist now or in the future in any
          jurisdiction, including without limitation all applications and
          registrations thereof.

    2.1.2 IMS shall have and retain all ownership, right, title, interest, and
          all Intellectual Property Rights and proprietary rights of every kind
          whatsoever in and to all Products and IMS Property shall under no
          circumstances be deemed to be "joint works of authorship," "works made
          for hire," or any other designation tending to imply that dodo has or
          retains ownership or authorship rights therein or thereto. To the
          extent that any such rights vest initially with dodo by operation of
          law or for any other reason, dodo hereby perpetually and irrevocably
          assigns, transfers, and quitclaims all such rights to IMS.

    2.1.3 dodo shall retain all ownership, right title, interest, and all
          Intellectual Property Rights and proprietary rights of every kind in
          and to all dodo Products. dodo will provide IMS with all data,
          including but are not limited to, test results; marketing data; and,
          further research and development of dodo Products upon request of IMS
          on an as needed basis. Dodo Products shall under no circumstances be
          deemed to be "joint works of authorship," "works made for hire," or
          any other designation tending to imply that dodo has or retains
          ownership or authorship rights therein or thereto.

<PAGE>
                      ARTICLE 3 - LICENSE GRANT (Territory)

3.1  dodo shall be granted exclusive right to use Axen for developing,
     manufacturing, marketing and distribution of dodo Products within Korea and
     shall further be granted non-exclusive marketing and distribution rights of
     the Axen based dodo Products to any established dodo distribution channel
     in countries other than Korea. Dodo is hereby strictly prohibited from
     reselling or redistribution of Axen to any entity other than dodo.

3.2  The Agreement does not prohibit foreign cosmetic manufacturers marketing
     and distributing their own Axen based formulation in Korea. However, IMS
     agrees to protect the Korean market for dodo by providing a temporary ban
     of any sales of Axen based cosmetics manufactured by foreign makers within
     anywhere in Korea, until August 31, 2002 provided that the launching of the
     dodo Product occurs before September 1, 2001.

                    ARTICLE 4 - ROYALTIES AND OTHER PAYMENTS

4.1  Research & Development Reimbursement (Lumpsum): In consideration of the
     rights being granted herein, dodo shall pay IMS in the amount of $200,000
     USD to be wire transferred to IMS designated account in appropriate
     currency at the exchange rate available at the time of payment. This
     payment shall be designated as dodo's payment for reimbursing IMS for Axen
     related research and Development costs and shall be paid according to the
     following schedule:

    4.1.1 10% or $20,000 USD to be paid at the time of signing the Agreement
          (Mar. 4, 2001). This initial 10% payment is refundable within first 90
          days or before June 5, 2001 should dodo decide not to pursue further
          on this Agreement. However, the 10% payment shall be non-refundable
          for any reason after June 5, 2001. The refund if necessary shall be
          paid by IMS within 30 days of dodo's notice to IMS;

    4.1.2 30% or $60,000 USD to be paid within 10 days of the approval from
          Korean Food & Drug Administration as to the safety of the dodo
          Products. dodo shall be responsible for the due diligence proceeding
          of the development of dodo Products and subsequent governmental
          approval process;

    4.1.3 30% or $60,000 USD shall be paid on or before September 1, 2001
          provided that the KFDA has made final approval. This 30% is payable
          regardless of the status of the dodo Products launch ; and,

    4.1.4 remaining 30% or $60,000 USD shall be paid exactly one year from the
          launching of dodo Products unless the Parties have mutually agreed to
          terminate the Agreement prior to the one year from launch date.

    4.1.5 The foregoing R&D Reimbursement shall be deducted from the royalty
          due IMS at the rate of: 40% deduction for the first calendar year of
          this Agreement ending on December 31, 2001; additional 40% deduction
          for the second calendar year period from January 1, 2002 through
          December 31, 2002; and, the remaining 20% deduction for the third
          calendar year period from January 1, 2003 through December 31, 2003.
          The deduction under this Section 4.1.5 shall be on royalty payment
          alone and if a royalty for the said time period is less than the
          deduction to be made for the same time period, it shall accrue for the
          deduction on the subsequent calendar year thereafter.
<PAGE>
4.2  Royalty: Further in consideration of the rights being granted herein, dodo
     shall pay royalties to IMS for Axen according to the following schedule and
     terms:

    4.2.1 The royalty shall be payable out of the Net Sales of dodo Products.
          Net Sales is defined as dodo's gross sales of the Axen based dodo
          Products less 15% of the dodo's gross sales less Axen raw material
          costs incurred by dodo [dodo gross sales - (15% + Axen raw material
          cost)] for the period;

    4.2.2 The royalty for the first year is set at XXX% of the Net Sales;

    4.2.3 The royalty for the second year of operation is set at XXX% of the Net
          Sales;

    4.2.4 The royalty for the third year of operation is set at XXX% of the Net
          Sales;

    4.2.5 The royalty for the fourth year of operation is set at XXX% of the Net
          Sales;

    4.2.6 The royalty for the fifth year of operation is set at XXX% of the Net
          Sales;

    4.2.7 The royalty shall be paid semi-annually (every two quarters). The
          first royalty payment shall be calculated based on the Net Sales from
          the launch date to the end of December, 2001 and thereafter. dodo must
          provide the royalty report for approval to IMS no later than fifteen
          (15) days from the completion of accounting on the previous quarter.
          The royalty payment then must be wire transferred to IMS account
          within fifteen (15) days of IMS' approval of dodo's report;

    4.2.8 Any adjustment necessitated by dodo's overpayment or underpayment of
          royalties shall be made within a reasonable time after discovery of
          such overpayment or underpayment;

    4.2.9 Parties agree to adhere with all applicable laws governing the
          taxation on royalties hereunder. Furthermore, any tax withholdings on
          royalties mandated by applicable laws shall be deducted accordingly by
          dodo with proper tax credits issued to IMS.

                        ARTICLE 5 - TERM AND TERMINATION

5.1  The Term of the Agreement shall be for five (5) years from the launching of
     the dodo Product provided that the launching of the dodo Product occurs
     before September 1, 2001. Any extension of this Agreement must be
     re-negotiated between the Parties at least six (6) months prior to the
     expiration of the Agreement.

5.2  Agreement Assignment to IMSA: Upon the establishment of IMSA and the
     completion of the Joint Venture relationship between IMS and IMSA, all
     rights, obligations, terms and provisions of this Agreement will be fully
     assigned to IMSA and IMSA shall thereafter assume the rights and
     obligations of IMS under this Agreement. Dodo acknowledges and fully
     accepts that IMS may assign this Agreement to IMSA at IMS's sole
     discretion. However, assignment to IMSA specified hereunder shall not
     relieve IMS of the claims arising out of Axen product liabilities. Parties
     agree that as the future assignee of this Agreement, IMSA shall be a
     signatory of this Agreement.

5.3  Axen Price & Required Minimum Purchase: As the initial pricing point, IMS
     guarantees the following price to dodo in return for dodo's purchase of the
     following minimum quantities:
<PAGE>
    5.3.1 One 55 gallon barrel of Axen at 100 PPM solution priced at $XXXXXX
          USD;

    5.3.2 dodo to purchase minimum of 40 barrels for the next three years at
          the price stated in Section 5.3.1 above, and minimum of 12 barrels in
          the first twelve (12) months of Effective Date and fourteen (14)
          barrels minimum per each succeeding twelve months increment;

    5.3.3 When and if a more favorite price than the price of Section 5.3.1
          above is negotiated between IMS and Foretech of Hong Kong, dodo shall
          immediately benefit by receiving the Foretech price for dodo's
          subsequent purchases of Axen.

    5.3.4 dodo is strictly prohibited from discussing, revealing or divulging
          the price as specified in section 5.3.1 above to any party not a
          signatory to this Agreement.

5.4  Termination by IMS: The license rights granted to dodo by virtue of this
     Agreement can be terminated in whole or in part by IMS at any time by
     notifying dodo with the Defects for such termination at a ninety (90) days'
     notice to dodo. dodo shall then have the right to cure the Defects to the
     satisfaction of IMS within the ninety (90) days notice period. Upon curing
     the Defects satisfactorily by dodo within the notice period, IMS shall not
     terminate the Agreement for the Defects. If no actions to cure the Defects
     are taken by dodo, the termination will be effective at the conclusion of
     such ninety (90) day Notice. For the purposes of this Section 5.4, Defects
     shall mean: (1) bankruptcy of dodo; (2) insolvency of dodo; (3) any
     fraudulent acts of dodo; and, (4) default on payments of royalty and other
     payments.

5.5  Termination for Breach: Either party may terminate this Agreement on sixty
     (60) days' prior written notice if the other party is in default or breach
     of any material provision of this Agreement, provided, however, that if the
     other party causes or diligently commences to cure the breach or default
     within such sixty (60) day period, this Agreement shall continue in full
     force and effect. Failure to terminate this Agreement for any default or
     breach shall not constitute a waiver by the aggrieved party of its right to
     terminate the Agreement for any other default or breach. Upon breach by
     dodo and the subsequent termination by IMS, the provisions of section 4.1.5
     above shall be vacated in its entirety. Upon breach by IMS, dodo shall have
     the right to bring necessary legal claims against IMS.

5.6  Continuing Rights: No termination of this Agreement shall affect the rights
     of IMS to earned royalty payments and any other payments due IMS.
     Confidentiality obligations pursuant to Article 9 herein shall survive
     termination of this Agreement.

5.7  Cessation of Marketing: If dodo ceases efforts to market and sell dodo
     Product for a period of one (1) Quarter in an commercially reasonable
     manner as represented in dodo's Marketing Plan to be provided by dodo as
     specified in section 6.2 below, through no fault of IMS, IMS shall have the
     right to terminate this Agreement immediately with a notice given to dodo
     and the provisions of section 4.1.5 shall be vacated in its entirety.

5.8  Right to Sell-off Inventory: Upon termination of this Agreement for any
     reason dodo shall have the right to sell-off any remaining inventory of
     dodo Product subject to all the terms and conditions.

                        ARTICLE 6 - DUTIES OF THE PARTIES

6.1  Product Development Costs: dodo shall manage and fund further development
     of dodo Products at its discretion. Dodo shall be responsible for
     development of approximately ten (10) cosmetic products utilizing Axen for
     dodo's premium brand.
<PAGE>
6.2  Marketing Plan: dodo shall provide IMS with dodo's marketing plans
     detailing the future planned marketing efforts throughout the term of this
     Agreement to be reviewed by IMS in advance, before or on June 1, 2001and
     the marketing plan, and dodo's performance thereof shall be attached to
     this Agreement as APPENDIX A.

6.3  Manufacturing: dodo shall be solely responsible for manufacturing,
     advertising, promoting, pricing and selling dodo Products in the Territory
     during the Term.

6.4  Regulatory Approval: dodo shall use diligent efforts to obtain, at its own
     expense, any necessary regulatory approval required to market dodo
     Products.

6.5  Trademark Supervision: dodo shall provide samples of dodo Product bearing
     any IMS or Silverion trademark to IMS prior to offering such dodo Product
     for sale to third parties. dodo further agrees to give IMS access to dodo
     manufacturing facilities, to permit IMS to determine and assure that a
     consistently high level of quality is maintained for all Products that bear
     a licensed IMS or Silverion trademark. IMS shall be responsible for
     registration of Silverion trademark in countries other than Korea at IMS's
     own expense. IMS further grants and dodo shall have no restrictions to use
     Silverion trademark on a world-wide basis for dodo Products.

6.6  Technology Support: IMS shall provide dodo with all necessary support in
     order for dodo to develop dodo Products utilizing Axen. Such support shall
     include but are not limited to all test conducted by IMS or independent lab
     in so far as it is related to the development of dodo Product in IMS's sole
     discretion; provision of IMS formula chemist; free and clear dialogs
     between dodo engineers IMS engineers; and, any proprietary information
     reasonably necessary for the development of dodo Products.

    6.6.1 On-Site Support: upon request by dodo, IMS shall make available IMS's
          formula chemist, engineers and marketing staff to visit dodo's
          facilities in an effort to develop dodo Product as necessary. Upon
          such visitation, IMS shall be responsible for all transportation costs
          for up to two (2) visits in any calendar year and dodo shall be
          responsible for the cost of room and board of such staff during their
          official visitation period. dodo shall be responsible for
          transportation and room and board of any further on-site support
          beyond the two(2) visits per calendar year specified above.

                  ARTICLE 7 - WARRANTIES AND INDEMINIFICATIONS

7.1  IMS Warranties: IMS hereby warrants that it has the right to enter into
     this Agreements and that no other party has any other interest in the
     subject matter hereof. IMS further warrants that it is not under any
     pre-existing obligations inconsistent with the provisions of this
     Agreement.

    7.1.1 Additional IMS Warranties: As of the Effective Date, IMS warrants
          that: (1) there are no fact or circumstance that may make any Patent
          invalid or unenforceable; (2) there are no other patent rights that
          may prevent dodo from using Product; (3) there are no claims,
          judgements, or settlements to be paid by IMS or pending claims
          relating to any patent; and (4) there are no infringement of any
          Patent by any third party in the Territory.

    7.1.2 Nothing in this Agreement shall be construed as an obligation to
          furnish any manufacturing process information except as otherwise
          specified under Section 6.6.

    7.1.3 Nothing in this Agreement shall be construed as a representation that
          any Product or any trademark will support the successful promotion,
          marketing or sale of the dodo Product.
<PAGE>
7.2  dodo Warranties: dodo hereby warrants that it has the right to enter into
     this Agreements and that no other party has any other interest in the
     subject matter hereof. dodo further warrants that it is not under any
     pre-existing obligations inconsistent with the provisions of this
     Agreement.

    7.2.1 Additional dodo Warranties: As of the Effective Date, dodo warrants
          that: (1) there are no fact or circumstance that may make any Patent
          invalid or unenforceable; (2) there are no other patent rights that
          may prevent dodo from using Product; (3) there are no claims,
          judgements, or settlements to be paid by dodo or pending claims
          relating to any patent; and (4) there are no infringement of any
          Patent by any third party in the Territory.

    7.2.2 Nothing in this Agreement shall be construed as an obligation to
          furnish any manufacturing process information except as otherwise
          specified under Section 6.6.

    7.2.3 Nothing in this Agreement shall be construed as a representation that
          any Product or any trademark will support the successful promotion,
          marketing or sale of the dodo Product.

7.3  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED HEREIN, THE PARTIES EXPRESSLY
     DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION,
     WARRANTIES OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.

7.4  Indemnification by dodo: dodo shall indemnify, defend and hold harmless IMS
     and its officers, agents, servants and employees against any and all claims
     of or liabilities to third parties, including expenses and costs of claims
     and suits for any such third party's loss, damage, injury or loss of life,
     if such claims or liabilities:

    7.4.1 arise from commercial sale of any dodo Products;

    7.4.2 arise from actions of dodo or its officers, servants, or agents, or
          third parties acting on behalf of or under authorization from in the
          performance of this Agreement; or,

    7.4.3 Arise from the breach of this Agreement by dodo.

    7.4.4 Notification of Claim dodo shall promptly notify IMS upon dodo's
          receipt of notification of claims or liabilities described herein and
          shall cooperate fully with IMS , at dodo's expense, in the defense of
          such claims.

7.5  Indemnification by IMS: IMS shall indemnify, defend and hold harmless dodo
     and its officers, agents, servants and employees against any and all claims
     of or liabilities to third parties, including expenses and costs of claims
     and suits for any such third party's loss, damage, injury or loss of life,
     if such claims or liabilities:

    7.5.1 arise from commercial sale of Axen;

    7.5.2 arise from actions of IMS or its officers, servants, or agents, or
          third parties acting on behalf of or under authorization from in the
          performance of this Agreement; or,

    7.5.3 Arise from the breach of this Agreement by IMS.

    7.5.4 Notification of Claim IMS shall promptly notify dodo upon IMS's
          receipt of notification of claims or liabilities described herein and
          shall cooperate fully with dodo, at IMS's expense, in the defense of
          such claims.
<PAGE>
7.6  Reimbursement: As the Parties intend full indemnification, all costs,
     expenses and fees, including attorney's fees and disbursements, incurred in
     enforcing this Article 7 shall also be reimbursed. Upon filing of any such
     claim or suit, aggrevied Party shall immediately notify the other Party
     thereof and the non-damaged Party may defend or settle any such action, or
     any part thereof brought against the damaged Party or pay damaged Party's
     counsel to defend same. Both parties' obligations under this Section are
     conditioned upon its being given (i) prompt notice of each such claim
     received in writing by either Party; and, (ii) the right to control and
     direct the investigation, defense and settlement of each such claim. The
     provisions of this Section shall survive the termination of this Agreement.

7.7  Claims by Third Parties: In the event a party to this Agreement is
     threatened with a suit by a third party rising out of this Agreement, the
     party being threatened shall give prompt Notice to the other party. The
     parties agree to confer together in such event and consult with one another
     with respect to the action to be taken.

                     ARTICLE 8 - CONFIDENTIALITY PROVISIONS

8.1  Confidentiality: IMS and dodo realize that some information received by one
     party from the other pursuant to this Agreement may be Confidential
     Information. Parties are responsible for specifying which information being
     provided are confidential in nature. Any Confidential Information shall not
     be disclosed by the receiving party to any third party and shall not be
     used by the receiving party for purposed other than those contemplated by
     this Agreement for a period of three (3) years from the cessation of this
     Agreement.

8.2  Additional Confidentiality Provisions: With respect to the Confidential
     Information provisions set forth in Paragraph 8.1:

    8.2.1 each party will use that level of care to prevent the use or
          disclosure of the other party's Confidential Information as it
          exercises in protection its own Confidential Information.

    8.2.2 Notwithstanding the foregoing dodo is permitted to disclose and use
          such Confidential Information to the extent reasonable necessary to
          exercise dodo license hereunder, provided that the Confidential
          Information is made subject to confidentiality restrictions consistent
          with those in this Agreement

    8.2.3 Upon termination of this Agreement each party shall return to the
          other or destroy all Confidential Information as to which the
          obligation of confidentiality has not expired, together with all
          copies and other forms of reproduction, except that a single archive
          copy of such Confidential Information my be retained by each party to
          monitor compliance with this Agreement.

8.3  Limitations on Confidentiality: The restrictions imposed under this
     Agreement shall not apply to the disclosure of any information necessary to
     obtain patents on inventions of the parties relating to the subject matter
     of this agreement, or to comply with the Korean or US laws or regulations,
     including, but not limited to, Korean and US laws governing the
     registration and sale of securities.

8.4  No Use of the name, of either party in any form of promotion or in
     connection with the sale of products, processes, devices, or designs or in
     license negotiations with third parties is permitted without prior written
     approval from the other party.

<PAGE>
                               ARTICLE 9 - NOTICE

9.1  Notice: Notices to either Party required under the Agreement shall be in
     writing and shall for all purposes be deemed to be fully given and received
     by a party if actually received by such party or on the fifth (5th) day
     after mailing by express air mail, to such party at its address set forth
     above or to such other person or persons or address as may be designated by
     such party from time to time by written notice given as provided herein.

9.2  Oral Notice Ineffective: Notice not given in writing shall not be effective
     against the party to whom such Notice was given.

                           ARTICLE 10 - MISCELLANEOUS

10.1 Choice of Law and Forum: All disputes, controversies, or differences which
     may arise between the Parties, out of or in relation to or in connection
     with this Agreement, or for the breach thereof, shall be finally settled by
     arbitration or a court of confident jurisdiction in Korea. This Agreement
     shall be interpreted and construed and the legal relations created herein
     shall be determined in accordance with the laws of the Republic of Korea.

10.2 Parties are Independent: Nothing in this Agreement shall be construed or
     interpreted as creating an agency, partnership, joint venture or similar
     business relationship between IMS and dodo. It is understood that the
     parties hereto are independent contractors with respect to each other and
     engage in the conduct of their own respective businesses. Neither party
     shall have any responsibility for the hiring, termination, compensation or
     benefits of the other party's employees. Neither IMS nor dodo is to be
     considered the agent or employee of the other for any purpose, and neither
     party has the right or authority to enter into any contracts or assume
     obligations for the other or to give any warranty or make any
     representation on behalf of the other party except where and to the extent
     specifically authorized in writing to do so.

10.3 Severability: Should any provision of this Agreement be held unenforceable
     or in conflict with the law of any jurisdiction, the validity of the
     remaining provisions shall not be affected by such holding.

10.4 Merger and Integration: This Agreement embodies the entire understanding
     between the parties and merges all prior discussions between them, and
     neither party shall be bound by any definition, condition, warranty,
     representation or term other then as expressly stated in this Agreement or
     as subsequently or concurrently set forth in a writing signed by duly
     authorized representative of the parties hereto.

10.5 Counterparts: This agreement can be executed in any number of counterparts,
     each of which shall be deemed on original hereof, but all of which shall
     constitute one and the same instrument.

10.6 No Waiver of Rights: No waiver of any term, provision, or condition of this
     Agreement, whether by conduct or otherwise, in any one or more instances,
     shall be deemed to be construed as a further or continuing waiver of any
     such term, provision, or condition of this Agreement.

10.7 Force Majeure: Neither Party shall be liable hereunder to the other Party
     nor shall be in breach for failure to deliver, provided failure to deliver
     is no greater than the delay in time caused by circumstances beyond control
     for either party, including but not limited to acts of God, fires, floods,
     riots, wars, civil disturbances, sabotage, accidents, labor disputes,
     government actions (including but not limited to priorities, requisitions,
     allocations and price adjustment restrictions).

10.8 Further Assurance: The parties hereto shall each perform such acts, execute
     and deliver such instruments and documents and do all such other things as
     may be reasonably necessary to accomplish the transactions contemplated in
     this Agreement. The parties shall cooperate in all respects and, to the
     extent possible, have their employees testify when requested and make
     available relevant records, papers, information, samples, specimens, and
     the like.
<PAGE>
10.9 Records and Audit Rights: During the term of this Agreement and for five
     (5) years thereafter, dodo shall keep, complete, true and accurate records
     containing all the particulars that may be necessary to enable royalties
     payable to IMS hereunder to be determined, and permit said records to be
     inspected at any time during regular business hours, upon reasonable
     notice, but in no event more frequently than once during any twelve (12)
     month period, by an independent auditor appointed by IMS for this purpose
     and acceptable to dodo who shall report to IMS only the amount of royalty
     payable hereunder. This audit shall be at IMS expense unless audit shows an
     underpayment in amounts due IMS by five percent (5%) or more for any
     six-month royalty period in the periods subject to audit, in which case the
     reasonable costs of such audit shall be borne by dodo. The results of any
     such audit shall be Confidential Information.

10.10 Successors & Assigns: this Agreement shall bind and inure to the benefit
      of the heirs, successors and assigns of the parties hereto.

10.11 No Strict Construction: This Agreement has been prepared jointly and shall
      not be strictly construed against either part.

10.12 Consent Not Unreasonably Withheld: Whenever provision is made in this
      Agreement for either party to secure the consent or approval of the other,
     such consent or approval shall not unreasonably be withheld or delayed, and
      whenever in this Agreement provision is made for one party to object to or
      disapprove a matter, such objection or disapproval shall not unreasonably
      be exercised or delayed.

10.13 Bankruptcy: At least ninety (90) days prior to filing a petition in
     bankruptcy, each Party must Notify the other of its intention to file a
     petition in bankruptcy or, if known through statements or letters from a
     creditor or otherwise. A Party's failure to perform this obligation shall
     be deemed to be a material pre-petition incurable default and breach under
     this Agreement.

10.14 Assignment: Except for the provisions of section 5.2 above, neither Party
     shall transfer or assign any of its rights or delegate any of its
     obligations hereunder, in whole or in part, whether voluntarily or by
     operation of law, without the written consent of the other Party. Any
     purported transfer, assignment, or delegation by either Party without such
     or written consent shall be null and void ab initio and of no force or
     effect. Notwithstanding the foregoing, without securing such consent,
     either Party may upon written notice to the other Party assign this
     Agreement and its rights and obligations hereunder to any successor of such
     first Party by way of merger, consolidation, or the acquisition of
     substantially all of such first Party's business and assets relating
     hereto.

10.15 Singular and Plural: The use herein of the singular form shall also denote
     the plural form, and the use herein of the plural form shall denote the
     singular form as in each case the context may require.

10.16 Headings: The headings of the Articles of this Agreement are inserted for
     convenience only, and shall not constitute a part hereof.

10.17 References: All references herein to articles, section paragraphs and
     attachments shall be to articles, section paragraphs and attachments of
     this Agreement.

10.18 No Finder's Fee: The parties acknowledge that no "finder" has been
     involved in bringing the parties together and that no compensation is due
     to any third party(s) as a result of the execution of this Agreement.

10.19 Third Party Royalties: Except as otherwise expressly provided herein dodo
     shall not be liable for any royalty payments to any third party.

10.20 Costs of Agreement: The parties hereto shall each bear their own costs and
     expenses (including attorneys' fees) incurred in connection with the
     negotiation and preparation of this Agreement and consummation of the
     transactions contemplated hereby.
<PAGE>
10.21 Amendment.: This Agreement shall not be amended, modified, or supplemented
     by the Parties in any manner, except by an instrument in writing signed on
     behalf of each Party and otherwise as set forth herein.

IN WITNESS WHEREOF, the parties hereto have caused this instrument to be signed
in duplicate by their duly authorized officers.

Innovative Medical Services, Inc.               dodo & Company
Michael Krall, President                        Gyu Gun Choi, President
1725 Gillespie Way,                             Dabo Bldg., 577 Shinsa-Dong,
El Cajon, CA 92020                              Kangnam-Ku, Seoul, Korea

Sign: /s/ Michael L. Krall                      Sign:/s/ G. G. Choi
--------------------------                      -------------------
Date: 3/16/01                                   Date:3/5/01

                    Innovative Medical Services Asia (under incorporation)
                    Min Sang Lee, President
                    Hanra Classic Officetel, Suite 710, Yeoksam-Dong,
                    Kangnam-Ku, 824-11, Seoul, Korea

                    Sign: /s/ Min Sang Lee
                    ----------------------
                    Date: 3/16/01

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]